Goodwin-Steered Akrevia Rebrands, Nabs $100.5M Funding
Life sciences company Akrevia Therapeutics said Monday it had raised $100.5 million in a Goodwin Procter-steered Series B financing and is rebranding as Xilio Therapeutics Inc. to reflect its push to...To view the full article, register now.
Already a subscriber? Click here to view full article